New Board & Chairman Proposal, Tecan Removed From STOXX 600, Stock OutlookExplore Tecan Group AG’s latest corporate governance changes, its STOXX 600 exclusion, and stock performance insights for investors in 2026.Tecan Group AG Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 25/03/2026, 07:30 2 minutes to read
Tecan Group AG Achieves Mid-Single-Digit Revenue Growth in Q3 2025, Maintains Full-Year OutlookTecan Group AG reported mid-single-digit revenue growth in Q3 2025, reaffirming its full-year 2025 outlook despite segment-level variations.Tecan Group AG Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 13/10/2025, 06:40 2 minutes to read
Tecan Group AG Reports Mixed Financial Results Amid Market VolatilityTecan Group AG reported a mixed financial performance for the first half of 2025, with a 3.7% sales decline, but remains optimistic about its future in the Life Sciences sector.Tecan Group AG Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 12/08/2025, 12:29 3 minutes to read